A 83-01 (ALK-5 Inhibitor): Selective Suppression of TGF-β Signaling

Executive Summary: A 83-01 is a small-molecule inhibitor that targets activin receptor-like kinase 5 (ALK-5), a key mediator of transforming growth factor-beta (TGF-β) signaling (source: product_spec). The compound exhibits high potency, inhibiting ALK-5-induced Smad transcription with an IC₅₀ of ~12 nM in cell-based assays (source: product_spec). Importantly, A 83-01 shows minimal cross-reactivity with BMP-induced pathways at standard concentrations, supporting its selectivity (source: product_spec). It is widely used to dissect mechanisms of EMT, fibrosis, and cellular growth inhibition in both 2D and 3D models (source: paper). APExBIO supplies A 83-01 at >98% purity, confirmed by HPLC, MS, and NMR (source: product_spec).

Biological Rationale

The TGF-β signaling pathway orchestrates cell growth, differentiation, and tissue remodeling. Dysregulation of this pathway is implicated in cancer progression, fibrosis, and the induction of epithelial-mesenchymal transition (EMT). Selective inhibition of ALK-5, the TGF-β type I receptor, is a validated approach to suppressing pathogenic TGF-β/Smad signaling. A 83-01 enables researchers to dissect the contribution of ALK-5-driven effects in both basic and translational models, including advanced organoid systems (source: paper).

Mechanism of Action of A 83-01 (ALK inhibitor)

A 83-01 is a small-molecule inhibitor with high selectivity for ALK-5 (TGF-β type I receptor), as well as ALK-4 and ALK-7, but does not significantly inhibit BMP pathway kinases at standard concentrations. It binds the kinase domain of ALK-5, preventing phosphorylation of receptor-regulated Smads (R-Smads; Smad2/3). This blockade halts downstream transcriptional activation of TGF-β target genes. In Mv1LuR4-2 cell-based luciferase assays, 1 μM A 83-01 suppressed ALK-5-driven reporter activity by 68% (source: product_spec), highlighting its effectiveness in canonical TGF-β signaling modulation. The compound's selectivity is evident, as BMP-induced transcription remains largely unaffected at ≤1 μM (source: product_spec).

Evidence & Benchmarks

• A 83-01 inhibits ALK-5-mediated Smad-dependent transcription with an IC₅₀ of ~12 nM in cell-based assays (source: product_spec).
• At 1 μM, A 83-01 reduces ALK-5-driven luciferase reporter activity by 68% in Mv1LuR4-2 cells (source: product_spec).
• The compound has minimal effect on BMP4-induced transcription at concentrations ≤1 μM but shows partial BMP4 suppression above 3 μM (source: product_spec).
• A 83-01 is validated as a TGF-β pathway inhibitor in 3D breast cancer organoid cultures, supporting drug sensitivity and mechanistic studies (source: paper).
• High purity (>98%) confirmed by HPLC, MS, and NMR, ensures reproducibility in biological assays (source: product_spec).

For researchers seeking deeper mechanistic context, this article on strategic TGF-β inhibition with A 83-01 examines translational strategies for modulating EMT and fibrosis, while the present article emphasizes workflow integration and selectivity in organoid models.

Applications, Limits & Misconceptions

A 83-01 is widely used in studies of TGF-β/Smad signaling, EMT, fibrosis, and cellular growth inhibition. Its high selectivity enables use in both 2D and 3D culture systems, including organoid models derived from human tissues such as breast adenomyoepithelioma (source: paper). The compound’s solubility profile—≥21.1 mg/mL in DMSO and ≥9.82 mg/mL in ethanol (with warming/sonication)—supports a range of experimental workflows (source: product_spec).

Common Pitfalls or Misconceptions

• A 83-01 is not suitable for direct inhibition of bone morphogenetic protein (BMP) signaling at standard concentrations. Inhibition occurs only at higher, potentially off-target concentrations (source: product_spec).
• The compound is insoluble in water; improper solvent use can result in precipitation and assay failure (source: product_spec).
• Long-term storage of solutions is not recommended due to potential compound degradation (source: product_spec).
• A 83-01 does not reverse established fibrosis or EMT phenotypes but prevents or attenuates TGF-β-driven changes (source: workflow_recommendation).
• It is not a pan-kinase inhibitor; off-target effects are minimal but should be assessed in non-canonical pathway studies (source: workflow_recommendation).

For a discussion of A 83-01’s role in human iPSC-derived organoids and its differentiation from other ALK inhibitors, see A 83-01: Advanced ALK-5 Inhibition for Human iPSC-Derived.... This present article updates those findings by providing direct protocol guidance and clarifying selectivity boundaries.

Workflow Integration & Parameters

Protocol Parameters

• assay: ALK-5/Smad luciferase reporter | value_with_unit: 1 μM, 68% inhibition | applicability: Mv1LuR4-2 cells | rationale: Potent suppression of TGF-β-induced transcription | source_type: product_spec
• assay: Smad pathway inhibition IC₅₀ | value_with_unit: ~12 nM | applicability: In vitro enzymatic/cellular assays | rationale: Benchmark for effective TGF-β pathway blockade | source_type: product_spec
• assay: Organoid culture drug sensitivity | value_with_unit: 3D culture, recommended starting range 0.1–1 μM | applicability: Human breast or intestinal organoids | rationale: Effective modulation of TGF-β/EMT markers | source_type: paper
• assay: Compound solubility | value_with_unit: ≥21.1 mg/mL in DMSO, ≥9.82 mg/mL in ethanol (warmed/sonicated) | applicability: Stock solution preparation | rationale: Ensures assay reproducibility and avoids precipitation | source_type: product_spec
• assay: Storage conditions | value_with_unit: Solid at -20°C, solutions < -20°C, avoid long-term solution storage | applicability: All research settings | rationale: Maintains compound integrity | source_type: product_spec

For advanced integration strategies and discussion of cross-talk with WNT signaling, see Strategic Inhibition of TGF-β Signaling with A 83-01. This article extends those discussions by focusing on validated solubility and workflow parameters.

Conclusion & Outlook

A 83-01 (ALK inhibitor) from APExBIO is a validated, selective tool for dissecting TGF-β/Smad signaling and studying EMT, fibrosis, and organoid biology. Its robust potency, high selectivity, and validated purity enable reproducible results in both basic and translational research settings (source: product_spec). As organoid and cancer research continue to evolve, tools like A 83-01 will remain central for modeling disease, screening drugs, and clarifying the molecular underpinnings of cell fate transitions (source: paper). For detailed product specifications and ordering, visit the A 83-01 (ALK inhibitor) product page.